comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 19:21:30 - browse：425

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

hotspot

WSS

Venture capital firm's plans to take over Akron hospital face hurdles

Boston competes with Raleigh

As obesity drug market grows, telehealth companies court payers

Trans patients at the end of life deserve respect and dignity

Roche's accidental data boosts hopes for anti

Trans patients at the end of life deserve respect and dignity

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

California store owner shot dead in dispute over displaying Pride flag: Police

Duchenne breakthrough therapy leaves behind pioneering families

California store owner shot dead in dispute over displaying Pride flag: Police

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Pancreatic cancer early detection could be helped by AI

Jerome Adams on the need for new antivirals for Covid

Study: Spinal cord stimulation helps patients with paralysis walk again

The cancer drug shortage isn’t new — and neither are the solutions

FDA greenlights medical device to combat bladder issues

hotspot

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Listen: Vivek Ramaswamy's star turn & leaky drug data

California store owner shot dead in dispute over displaying Pride flag: Police

California store owner shot dead in dispute over displaying Pride flag: Police

Pancreatic cancer early detection could be helped by AI

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Wikipedia

hotspot

hotspot

knowledge